Mylan's stock gains 2%; guidance for 2020 reaffirmed


Shares of Mylan MYL, 0.87% gained 0.1% in premarket trading on Monday after the drugmaker reaffirmed its revenue guidance for the year. Mylan had earnings of $20.8 million, or 4 cents per share, in the first quarter of 2020, after a loss of $25 million, or 5 cents per share, in the same period a year ago. The FactSet consensus was 86 cents. Revenue rose 5% to $2.62 billion for the quarter, up from $2.50 billion a year ago. The FactSet consensus was $2.65 billion. The company said that it anticipates the Upjohn deal with Pfizer Inc. PFE, 0.26% will close in the second half of 2020. Like many drugmakers, Mylan reported an uptick in prescription drug sales in the second quarter as people stocked up on medicines before stay-at-home orders went into place. "We have estimated that the net impact of the pandemic increased net sales and consolidated revenue by approximately 2%," Mylan said. The company reaffirmed its 2020 guidance, saying it still expects revenue in the range of $11.5 billion and $12.5 billion. Mylan's stock is down 12.9% so far this year, while the S&P 500 SPX, -0.59% has declined 9.3%.